GFAP and myeloid sarcoma: Elevated serum GFAP levels have been demonstrated to be correlated with higher EDSS scores, increased MRI lesion load, and progression independent of relapse activity (PIRA), thereby underscoring its significance in tracking MS-related disability progression [37,38].